Evidence map›Paper›PMID 33982954›Full record

SynthesisThe American journal of gastroenterology2021

Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection.

Jacob E Kurlander, Geoffrey D Barnes, Devraj Sukul, Danielle Helminski, Alex N Kokaly, Kevin Platt, Hitinder Gurm, Sameer D Saini

Registry-linked trialOpen access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The American journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03719170 (Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03719170 nacompletednot on this map

Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2019 to 2021Enrolled220,306ConditionsProton Pump InhibitorsArmsPPI De-prescribing Program
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jacob E Kurlander1Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; 2VA Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan, USA; 3Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA; 4Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, USA; 5UCLA Health Department of Medicine, Los Angeles, California, USA.
Geoffrey D Barnes
Devraj Sukul
Danielle Helminski
Alex N Kokaly
Kevin Platt
Hitinder Gurm
Sameer D Saini
University of Michigan–Ann Arbor · USVA Center for Clinical Management Research · US

Funding

Using Intervention Mapping and the Multiphase Optimization Strategy to develop multilevel interventions to prevent upper GI bleedingK23DK118179 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KURLANDER, JACOB ELI · 2019 to 2023
$974k
Developing an Implementation Strategy to Improve Peri-procedural Anticoagulation Management for Patients with Atrial FibrillationK01HL135392 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARNES, GEOFFREY DOUGLAS · 2017 to 2021
$842k
NHLBI NIH HHS K01 HL135392NIDDK NIH HHS K23 DK118179
6 · The paper itself

Abstract

introductionGastrointestinal bleeding is a morbid complication of dual antiplatelet therapy (DAPT). We evaluated the extent to which contemporary trials of DAPT included steps to ensure appropriate use of proton pump inhibitor (PPI) gastroprotection and reported rates of PPI use.

methodsA methodological review of randomized trials comparing varying durations of DAPT after percutaneous coronary intervention.

resultsAmong 21 trials, none incorporated protocol procedures or guidance for prescribing PPIs. Five reported rates of PPI use (range 25.6-69.1%). DISCUSSION: PPI gastroprotection is overlooked in major trials of DAPT. Appropriate use of PPI gastroprotection represents an important opportunity to improve patient safety.

Indexed as

Clinical Trials as TopicPractice Guidelines as TopicDual Anti-Platelet TherapyHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative CareStomachStomach DiseasesPlatelet Aggregation Inhibitors

Identifiers

PMID33982954
PMCPMC8119932
OpenAlexW3125605531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.